ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Financial Statements and Exhibits

ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1

Press release dated December 6, 2018.


Adamis Pharmaceuticals Corp Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE   ADAMIS PHARMACEUTICALS CORPORATION 8-K   Exhibit 99.1    Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI   San Diego,…
To view the full exhibit click here

About ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

An ad to help with our costs